PROTAGONIST THERAPEUTICS, INC.

(PTGX)
  Report
Delayed Nasdaq  -  05/20 04:00:00 pm EDT
7.920 USD   +1.93%
05/18Piper Sandler Adjusts Price Target on Protagonist Therapeutics to $35 From $60, Reiterates Overweight Rating
MT
05/11SHAREHOLDER ALERT : Pomerantz Law Firm Investigates Claims On Behalf of Investors of Protagonist Therapeutics, Inc. - PTGX
PR
05/05PROTAGONIST THERAPEUTICS, INC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Protagonist Therapeutics Picks PN-235 for Mid-Stage Trials in Multiple Indications

12/02/2021 | 05:27pm EDT


© MT Newswires 2021
Stocks mentioned in the article
ChangeLast1st jan.
JOHNSON & JOHNSON 1.75% 176.98 Delayed Quote.1.68%
PROTAGONIST THERAPEUTICS, INC. 1.93% 7.92 Delayed Quote.-76.84%
All news about PROTAGONIST THERAPEUTICS, INC.
05/18Piper Sandler Adjusts Price Target on Protagonist Therapeutics to $35 From $60, Reitera..
MT
05/11SHAREHOLDER ALERT : Pomerantz Law Firm Investigates Claims On Behalf of Investors of Prota..
PR
05/05PROTAGONIST THERAPEUTICS, INC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDIT..
AQ
05/05SVB Leerink Adjusts Protagonist Therapeutics' Price Target to $30 from $50, Keeps Outpe..
MT
05/04PROTAGONIST THERAPEUTICS : Q1 Earnings Snapshot
AQ
05/04Protagonist Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended Mar..
CI
04/26Protagonist Therapeutics' Shares Plummet After Reporting Trial Data for Inflammatory Bo..
MT
04/26Top Midday Decliners
MT
04/26Top Premarket Decliners
MT
04/26PROTAGONIST THERAPEUTICS : Announces Topline Data from Phase 2 IDEAL Study of PN-943 in Ul..
PU
More news
Analyst Recommendations on PROTAGONIST THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2022 32,3 M - -
Net income 2022 -157 M - -
Net cash 2022 174 M - -
P/E ratio 2022 -2,50x
Yield 2022 -
Capitalization 385 M 385 M -
EV / Sales 2022 6,53x
EV / Sales 2023 19,9x
Nbr of Employees 122
Free-Float 98,6%
Chart PROTAGONIST THERAPEUTICS, INC.
Duration : Period :
Protagonist Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PROTAGONIST THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 7,92 $
Average target price 40,00 $
Spread / Average Target 405%
EPS Revisions
Managers and Directors
Dinesh V. Patel President, Chief Executive Officer & Director
Asif Ali Chief Financial Officer & Executive Vice President
Harold E. Selick Chairman
Mark L. Smythe Vice President-Technology
David Y. Liu Chief Research & Development Strategy Officer
Sector and Competitors
1st jan.Capi. (M$)
PROTAGONIST THERAPEUTICS, INC.-76.84%385
MODERNA, INC.-46.35%54 195
LONZA GROUP AG-27.84%41 796
IQVIA HOLDINGS INC.-28.46%38 202
SEAGEN INC.-9.68%25 704
ICON PUBLIC LIMITED COMPANY-30.22%17 567